A detailed history of Susquehanna International Group, LLP transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Susquehanna International Group, LLP holds 134,260 shares of PDSB stock, worth $221,529. This represents 0.0% of its overall portfolio holdings.

Number of Shares
134,260
Previous 135,455 0.88%
Holding current value
$221,529
Previous $396,000 29.29%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.93 - $4.23 $3,501 - $5,054
-1,195 Reduced 0.88%
134,260 $512,000
Q2 2024

Aug 15, 2024

SELL
$2.55 - $4.02 $136,963 - $215,918
-53,711 Reduced 28.39%
135,455 $396,000
Q1 2024

May 07, 2024

SELL
$3.85 - $6.59 $277,400 - $474,822
-72,052 Reduced 27.58%
189,166 $749,000
Q4 2023

Feb 14, 2024

BUY
$3.95 - $6.58 $318,689 - $530,880
80,681 Added 44.69%
261,218 $1.3 Million
Q3 2023

Nov 14, 2023

BUY
$4.8 - $6.4 $118,008 - $157,344
24,585 Added 15.76%
180,537 $911,000
Q2 2023

Aug 11, 2023

SELL
$5.03 - $9.9 $297,403 - $585,347
-59,126 Reduced 27.49%
155,952 $784,000
Q1 2023

May 16, 2023

BUY
$5.68 - $11.99 $550,477 - $1.16 Million
96,915 Added 82.02%
215,078 $1.32 Million
Q4 2022

Feb 14, 2023

BUY
$3.28 - $13.2 $193,749 - $779,724
59,070 Added 99.96%
118,163 $1.56 Million
Q3 2022

Nov 14, 2022

SELL
$2.97 - $5.79 $273,260 - $532,720
-92,007 Reduced 60.89%
59,093 $176,000
Q2 2022

Aug 15, 2022

BUY
$3.05 - $6.68 $43,645 - $95,590
14,310 Added 10.46%
151,100 $552,000
Q1 2022

May 16, 2022

SELL
$4.78 - $8.43 $767,237 - $1.35 Million
-160,510 Reduced 53.99%
136,790 $846,000
Q4 2021

Feb 14, 2022

SELL
$7.76 - $14.35 $295,485 - $546,419
-38,078 Reduced 11.35%
297,300 $2.41 Million
Q3 2021

Nov 15, 2021

BUY
$9.33 - $17.08 $1.94 Million - $3.55 Million
208,047 Added 163.39%
335,378 $5 Million
Q2 2021

Aug 11, 2021

BUY
$4.35 - $12.86 $553,889 - $1.64 Million
127,331 New
127,331 $1.6 Million

Others Institutions Holding PDSB

About PDS Biotechnology Corp


  • Ticker PDSB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,458,700
  • Market Cap $47M
  • Description
  • PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...
More about PDSB
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.